Do Ozempic and Wegovy weaken your bones? What the data shows

Headlines this month cannot agree on one thing: do GLP-1 medications like Ozempic and Wegovy weaken your bones, or not? One set of studies says fracture risk drops. Another, a fresh 5-year analysis of more than 73,000 patients, says osteoporosis and related bone problems show up more often. If you are on semaglutide or tirzepatide and trying to cut through the noise, here is what the evidence actually shows and what you can do about it starting this week.

TL;DR

The research on GLP-1 medications and bone health is genuinely mixed, but the newest long-term data links these drugs to a modestly higher rate of osteoporosis. That is not a reason to stop treatment. It is a reason to protect your bones on purpose, with enough protein, vitamin D, calcium, and resistance training.

What the newest 5-year data actually found

The study driving this month's headlines was presented at the 2026 AAOS Annual Meeting. Researchers pulled electronic medical records and built 73,483 matched pairs of patients, comparing people on GLP-1 receptor agonists against people who were not. The two groups were matched for age, sex, race, BMI, hemoglobin A1c, tobacco use, and other conditions, then followed for five years. Matching like this matters, because it strips out the easy explanations. If the GLP-1 group still shows more bone problems after you account for weight and blood sugar, the signal is harder to wave away.

Here is what they found over those five years:

• Osteoporosis: 4.1% of GLP-1 users versus 3.2% of matched controls, about a 29% higher relative risk.
• Osteomalacia (soft, poorly mineralised bone): 2.0% versus 0.1%, a large relative jump off a small base.
• Gout: 7.4% versus 6.6%, a smaller but statistically real increase.

The lead researcher's takeaway was measured, not alarmist. The message was to watch for these problems over time: "Whenever you have a patient prone to osteoporosis, gout or osteomalacia, clinicians should monitor for delayed-onset complications." In plain terms, the risk is real but manageable if someone is actually looking for it.

One number deserves a second look. The osteomalacia gap (2.0% versus 0.1%) sounds dramatic, and it is worth taking seriously, but the absolute rate is still low and this condition is closely tied to vitamin D and mineral status. That is a clue we will come back to, because it points straight at something you can influence.

It is not all bad news either. A companion study of ten common orthopaedic surgeries across a national claims database found GLP-1 users actually had fewer postoperative emergency department visits, lower surgical site infection rates for knee and hip replacement, and lower revision rates for knee replacement. So the same class of drug that nudges up osteoporosis risk also seems to help people recover better from surgery, most likely because losing weight takes load and inflammation off the joints. Bodies are complicated. One drug can push in two directions at once.

Why the studies seem to contradict each other

If a 5-year study shows more osteoporosis, why do other 2026 studies show fracture risk staying flat or even dropping? The answer is that bone density and fracture risk are not the same measurement, and rapid weight loss pulls on both.

When you lose a lot of weight quickly, some of what leaves your body is bone mineral and lean tissue, not only fat. This is the same mechanism behind muscle loss on Ozempic that gets so much attention. Researchers estimate that 25 to 30% of the weight lost on GLP-1 medications can be lean mass, and your skeleton adapts to carrying a lighter frame by shedding some density. On a bone scan, that shows up as lower numbers. Whether it translates into an actual broken bone depends on other things: how strong your muscles still are, how well you balance, how hard you fall, and how much cushioning fat you have left.

That is why the fracture findings are all over the map. Some analyses find no increase in fractures, and a few even find fewer, possibly because lighter people fall with less force and move more easily. Other studies flag higher fracture risk specifically in older adults, where thin bones and fall risk stack up. Researchers are still investigating exactly which patients are most exposed, and the honest summary right now is that the picture is early and unsettled. What almost every study agrees on is the underlying trend: bone density tends to drift down during fast weight loss unless you push back against it.

The other reason the studies diverge is who they looked at. A cohort of adults over 65 with type 2 diabetes will show a different bone story than a trial of healthy 40-year-olds. Age, sex, menopause status, and baseline vitamin D all shift the result. So when two headlines clash, the useful question is not "which one is right" but "which one describes someone like me."

How to protect your bones while on GLP-1 medications

Here is the good part. Almost everything that protects bone during weight loss is within your control, and it overlaps heavily with what protects muscle. A 2026 review in Clinical Nutrition ESPEN laid out the current playbook for eating well in the GLP-1 era, and it maps cleanly onto bone protection. These are the levers that matter most:

1. Hit your protein target every day. The review recommends at least 1.2 g/kg of body weight in protein daily, up to 1.6 g/kg for adults without kidney disease. For a 75 kg person that is roughly 90 to 120 grams a day. Just as important, spread it out: aim for 0.3 to 0.4 g/kg per meal, or around 25 to 40 grams at a sitting, with roughly 2.5 to 3 grams of leucine per meal to actually trigger muscle repair. Protein is not only muscle food. The protein matrix in bone is what mineral crystals attach to, so protein intake on Wegovy or Mounjaro supports the frame your bones are built on.
2. Do resistance training two to three times a week. This is the single most evidence-backed thing you can do for bone during weight loss. Progressive resistance training signals both muscle and bone to hold their ground instead of wasting away. Bodyweight squats, resistance bands, or dumbbells all count. You do not need a gym, you need consistency.
3. Cover vitamin D and calcium. Vitamin D controls how well you absorb calcium, and low vitamin D is one of the direct causes of the osteomalacia signal in the data above. Many people with obesity start out low on vitamin D before they ever pick up a pen injector. Calcium is the raw material bones are made from. If your appetite has dropped hard on a GLP-1 medication, you may simply not be eating enough dairy, leafy greens, or fortified foods to keep up.
4. Do not forget magnesium and vitamin B12. Magnesium is a quiet partner in bone metabolism and is easy to run low on when you are eating far less food. Vitamin B12 deficiency is common on semaglutide and affects energy and nerve health, which indirectly affects how active and steady on your feet you stay. Getting the right vitamins while on GLP-1 is less about megadoses and more about closing the gaps that appear when total food intake falls.
5. Ask for the blood panel. The ESPEN review recommends a structured lab check covering vitamin D, vitamin B12, iron studies, folate, zinc, and thiamine. You cannot fix a deficiency you never measured. If your prescriber has not run these, ask.

This is exactly the gap that targeted GLP-1 supplements are built to close. When you are eating a fraction of your old food volume, hitting protein, vitamin D, calcium, magnesium, and B12 from meals alone gets genuinely hard, and that is where a formulation designed for GLP-1 users earns its place. GLP-1 Shield was built around this specific problem: protecting the nutrients most likely to run low so your bones and muscle are not collateral damage of your weight loss.

None of this means the medication is the enemy. GLP-1 side effects like bone density loss are a signal to add support, not to quit a treatment that may be doing a lot of good elsewhere. The people who do best treat bone and muscle as things to actively defend, the same way they would guard against nausea or dehydration in the early weeks.

Frequently asked questions

Do Ozempic and Wegovy actually cause osteoporosis?

The newest 5-year data links GLP-1 medications to a modestly higher osteoporosis rate, 4.1% versus 3.2% in matched patients. The increase is real but small in absolute terms, and it appears closely tied to rapid weight loss and low vitamin D rather than a direct poison effect on bone. Protein, vitamin D, calcium, and resistance training can offset much of the risk.

Should I take calcium and vitamin D while on a GLP-1?

For most people, yes, though the right dose depends on your blood levels. Low vitamin D drives poor calcium absorption and is one of the direct causes of the soft-bone signal seen in the research. Ask your prescriber to check your vitamin D level and adjust from there rather than guessing.

How much protein do I need on Wegovy or Mounjaro?

Current guidance is at least 1.2 g/kg of body weight per day, up to 1.6 g/kg if your kidneys are healthy. Spread it across meals at roughly 25 to 40 grams each. Adequate protein protects both muscle and the protein framework inside your bones during fast weight loss.

Will bone loss reverse if I stop the medication?

This is still being studied. Bone responds slowly, and some density lost during rapid weight loss may not fully return, especially in older adults. That is the argument for protecting bone while you are on treatment rather than hoping to rebuild it later. Resistance training and adequate nutrition are the most reliable tools either way.